335 related articles for article (PubMed ID: 21733594)
1. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
[TBL] [Abstract][Full Text] [Related]
2. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
[TBL] [Abstract][Full Text] [Related]
3. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
Sholl LM; Yeap BY; Iafrate AJ; Holmes-Tisch AJ; Chou YP; Wu MT; Goan YG; Su L; Benedettini E; Yu J; Loda M; Jänne PA; Christiani DC; Chirieac LR
Cancer Res; 2009 Nov; 69(21):8341-8. PubMed ID: 19826035
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.
Wang Q; Lv Y; Zhong M; Zhu F; Wei L; Shi H
J BUON; 2017; 22(4):1053-1060. PubMed ID: 28952227
[TBL] [Abstract][Full Text] [Related]
7. MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.
Noro R; Seike M; Zou F; Soeno C; Matsuda K; Sugano T; Nishijima N; Matsumoto M; Kitamura K; Kosaihira S; Minegishi Y; Yoshimura A; Kubota K; Gemma A
BMC Cancer; 2015 Feb; 15():31. PubMed ID: 25886066
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
[TBL] [Abstract][Full Text] [Related]
9. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
[TBL] [Abstract][Full Text] [Related]
10. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
[TBL] [Abstract][Full Text] [Related]
12. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
13. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
15. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
17. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
19. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
